Future plans are to study XPro1595 in combination with RNA-targeting therapies (for example, tofersen (SOD1 ASOs) or ASOs targeting C9orf72) to achieve a combined effect of inhibiting neuroinflammation in addition to inhibiting protein-folding and proteotoxic stress associated with ALS [303]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.